SRR5088919
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- MYC_TARGETS_V1+0.400
- E2F_TARGETS+0.300
- MYOGENESIS+0.200
- SPERMATOGENESIS+0.200
- G2M_CHECKPOINT+0.100
- KRAS_SIGNALING_DN+0.100
- UNFOLDED_PROTEIN_RESPONSE+0.100
- ESTROGEN_RESPONSE_EARLY+0.000
- OXIDATIVE_PHOSPHORYLATION+0.000
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.700
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.500
- COMPLEMENT-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- APOPTOSIS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- IL2_STAT5_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_GS1KR5PK | medulloblastoma | — | 0.905 |
| 2 | s0112225 | — | — | 0.900 |
| 3 | BS_YEB88D32 | medulloblastoma | — | 0.892 |
| 4 | SRR5088911 | — | — | 0.891 |
| 5 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.890 |
| 6 | R16 | — | — | 0.889 |
| 7 | SRR8518301 | — | E | 0.888 |
| 8 | C3N-02283 | — | cohortMD1 | 0.887 |
| 9 | ERR2208946 | — | — | 0.886 |
| 10 | BS_ZXYDSBM9 | medulloblastoma | — | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |